1. Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis
   Szilárd Váncsa et al, 2021, Frontiers in Medicine CrossRef
2. A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
   Akio Miyasaka et al, 2021, International Journal of General Medicine CrossRef
3. Surveillance for hepatocellular carcinoma in chronic viral hepatitis: Is it time to personalize it?
   Coskun Ozer Demirtas et al, 2021, World Journal of Gastroenterology CrossRef
4. Efforts to identify HCV antibody-positive patients in a medium-sized hospital by "Team hepatitis" composed of hospital staff with a hepatitis medical care coordinator
   Joji Tani et al, 2021, Kanzo CrossRef
5. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals
   Roberta D'Ambrosio et al, 2021, Journal of Hepatocellular Carcinoma CrossRef
6. Risk of hepatocellular carcinoma after hepatitis C virus cure
   Maria Alejandra Luna-Cuadros et al, 2022, World Journal of Gastroenterology CrossRef
7. Revolution in the diagnosis and management of hepatitis C virus infection in current era
   F M Hanif et al, 2022, World Journal of Hepatology CrossRef
8. Association between direct-acting antiviral agents in hepatitis C virus treatment and hepatocellular carcinoma occurrence and recurrence: The endless debate
   Ahmed Kamal et al, 2022, World Journal of Clinical Cases CrossRef
9. Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
   Cristina Maria Muzica et al, 2020, World Journal of Gastroenterology CrossRef
10. Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents
    Ashraf Elbahrawy et al, 2023, Frontiers in Virology CrossRef